Medical Journal of the Islamic Republic Of Iran
مجله پزشکی جمهوری اسلامی ایران
Med J Islam Repub Iran
Medical Sciences
http://mjiri.iums.ac.ir
2
journal2
1016-1430
2251-6840
8
10.18869/mjiri
14
8888
13
en
jalali
1400
10
1
gregorian
2022
1
1
36
1
online
1
fulltext
en
Estimating the Prevalence of Bladder Cancer by Stage in Iran as a Developing Country
Biostatistics and Epidemiology
Biostatistics and Epidemiology
Original Research
Original Research
<strong>Background: </strong>Bladder cancer is among the 10 most common cancers globally and in Iran. The prevalence rate is a crucial metric for both estimating disease burden and policymakers. On the other hand, bladder cancer is a heterogeneous disease with different stages, high recurrence, and progression rate. In planning treatment procedures, it is important to know the prevalence of bladder cancer by stages. In the current study, we aimed to estimate the 5-year prevalence of bladder cancer by stages using the Markov model. <br>
<strong>Methods:</strong> This was a simulation study. To estimate the 5-year prevalence of bladder cancer by stages, we used the Markov model with a time horizon of 5 years following diagnosis. We simulated the natural history of bladder cancer using a literature review. We extracted survival rate, stage-specific recurrence, and progression rate using local and international publications and expert opinion. In addition, we used the Iranian life table and extracted probabilities of mortality due to other causes of death.<br>
<strong>Results:</strong> Five-year prevalence of bladder cancer for the year 2018 was estimated at 21,807 patients. Non- muscle-invasive bladder cancer accounted for around 68% of all cases, with 42% in the Ta low-grade stage. About 32% of bladder cancer prevalent cases were muscle-invasive bladder cancer patients, from which about 8% had metastatic tumors. <br>
<strong>Conclusion:</strong> Researchers and policymakers can utilize the findings of this study to conduct economic burden analyses and plan resource allocation.
Markov Model, Bladder Cancer, Prevalence, Stage, Epidemiology, Iran
283
287
http://mjiri.iums.ac.ir/browse.php?a_code=A-10-7104-1&slc_lang=en&sid=1
Hamideh
Rashidian
hmdhrashidian@yahoo.com
200319475328460069246
200319475328460069246
No
Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Ali Akbar
Haghdoost
ahaghdoost@gmail.com
200319475328460069247
200319475328460069247
No
Regional Knowledge Hub, and WHO Collaborating Centre for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
Rajabali
Daroudi
rdaroudi@yahoo.com
200319475328460069248
200319475328460069248
No
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Mehdi
Raadabadi
mehdiraadabadi@gmail.com
200319475328460069249
200319475328460069249
No
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Reza
Ebadzadeh
m.ebadzadeh@gmail.com
200319475328460069250
200319475328460069250
No
Department of Urology, Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran
Kazem
Zendehdel
kzendeh@tums.ac.ir
200319475328460069251
200319475328460069251
Yes
Cancer Research Center, & Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran